Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. (Q52838335)

8 May 2018

title

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. (English)

1 reference

8 May 2018

1 reference

1 reference

1 reference

Kan He

1

1 reference

8 May 2018

Joseph M Luettgen

2

1 reference

8 May 2018

Donglu Zhang

3

1 reference

8 May 2018

Bing He

4

1 reference

8 May 2018

James E Grace

5

1 reference

8 May 2018

Baomin Xin

6

1 reference

8 May 2018

Donald J P Pinto

7

1 reference

8 May 2018

Pancras C Wong

8

1 reference

8 May 2018

Robert M Knabb

9

1 reference

8 May 2018

Patrick Y S Lam

10

1 reference

8 May 2018

Ruth R Wexler

11

1 reference

8 May 2018

Scott J Grossman

12

1 reference

8 May 2018

publication date

2 April 2011

1 reference

8 May 2018

European Journal of Drug Metabolism and Pharmacokinetics

published in

1 reference

8 May 2018

volume

36

1 reference

8 May 2018

issue

3

1 reference

8 May 2018

page(s)

129-139

1 reference

8 May 2018

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Clinically important drug interactions with anticoagulants. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Warfarin therapy: in need of improvement after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Coagulation factor Xa inhibition: biological background and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

The design and synthesis of noncovalent factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Apixaban metabolism and pharmacokinetics after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Free drug concentration monitoring in clinical practice. Rationale and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Monitoring the new antithrombotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0037-X

Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma

21 January 2018

1 reference

12 December 2020

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

1 reference

12 December 2020

Physiological parameters in laboratory animals and humans

1 reference

12 December 2020

Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications

1 reference

12 December 2020

Emerging anticoagulants for the treatment of venous thromboembolism

1 reference

12 December 2020

Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

1 reference

12 December 2020

Kinetic aspects of the interaction of blood clotting enzymes. VII. The relation between clotting time and prothrombin concentration

1 reference

12 December 2020

10.1007/S13318-011-0037-X

Identifiers

DOI

1 reference

8 May 2018

1 reference

8 May 2018